IPF: How Fast Does It Progress and What Treatments Actually Slow It Down

Research-informed explainer — last updated April 12, 2026

Idiopathic pulmonary fibrosis is a progressive scarring disease of the lungs with no cure, but two FDA-approved antifibrotic medications — pirfenidone and nintedanib — have been shown in randomized trials to slow the rate of lung function decline by approximately 50%. The decision to start treatment early, and understanding why conventional anti-inflammatory drugs do not work, is the most important thing a newly diagnosed patient can grasp.

This article draws on research from Jeffrey Horowitz, MD, Director of the Division of Pulmonary, Critical Care and Sleep Medicine at Ohio State University and co-author of landmark mechanistic papers on fibrosis pathways; Timothy Blackwell, MD, at Michigan Medicine, who has published extensively on why IPF resists inflammation-based treatment; Serpil Erzurum, MD, at Cleveland Clinic, who has studied vascular biology in IPF; Mitchell Olman, MD, also at Cleveland Clinic, who led the pivotal randomized warfarin trial in IPF; and Sina Gharib, MD, Professor at the University of Washington, who characterized the cellular landscape driving fibrosis.

Why IPF Is Not an Inflammatory Disease — and Why That Matters

For decades, IPF was treated with corticosteroids and immunosuppressive drugs on the assumption that inflammation was the driver. It is not. The disease is now understood to be primarily a fibrotic process driven by abnormal fibroblast activation, extracellular matrix remodeling, and mechanical feedback loops — not immune cell infiltration.

Dr. Horowitz contributed to a Nature Medicine paper (cited 830 times) demonstrating that NADPH oxidase-4 (NOX4) drives the transformation of normal lung fibroblasts into activated myofibroblasts — the cells that deposit scar tissue. This transformation is triggered by TGF-beta signaling and amplified by oxidative stress, not by classical inflammatory cascades. The same group's YAP/TAZ mechanosignaling study (cited 785 times) showed that as lung tissue stiffens from early fibrosis, the mechanical signals transmitted to fibroblasts push them further into an activated state — creating a self-sustaining feedback loop that explains why fibrosis becomes progressively harder to stop.

Dr. Blackwell's work on endoplasmic reticulum (ER) stress in alveolar epithelial cells (cited 440 times) established that the cells lining the air sacs in IPF lungs are chronically stressed, misfolding surfactant proteins, and dying at an accelerated rate. This epithelial injury is the initiating event that activates the fibroblast cascade. ER stress, not inflammation, is the upstream driver. His 2018 Matrix Biology review (cited 329 times) synthesizes these insights and explains why epithelial-mesenchymal interactions define the therapeutic targets that are actually tractable.

How Fast Does IPF Progress?

Progression is highly variable. The classic teaching is that IPF follows a slow, steady decline in forced vital capacity (FVC) of roughly 150-200 mL per year on average. But the actual pattern is more heterogeneous: some patients have rapid, stepwise declines after acute exacerbations; others are stable for years and then deteriorate sharply. There is currently no imaging or biomarker that reliably predicts which trajectory a given patient will follow.

The strongest predictor of subsequent decline is the FVC slope over the first 6-12 months of observation. A decline of more than 10% in FVC over 12 months is associated with significantly higher mortality in multiple prospective cohorts. This is why early spirometric monitoring — every 3-6 months for newly diagnosed patients — is standard of care.

Dr. Gharib's work on lung pericytes and resident fibroblasts (cited 387 times) established that the cellular landscape of the fibrotic niche is populated by multiple distinct cell types, each contributing to the self-perpetuating nature of the process. Once established, fibrosis activates fibroblasts that weren't originally involved, expanding the scarred regions even without new injurious triggers.

Why Warfarin and Prednisone Do Not Work

The randomized trial of warfarin in IPF, co-led by Dr. Olman and published in the American Journal of Respiratory and Critical Care Medicine (cited 462 times), is one of the clearest examples in pulmonary medicine of a therapy backed by biological rationale that failed in clinical practice. The trial was stopped early because the warfarin group had a significantly higher rate of death and hospitalization compared to placebo. Anticoagulation had been proposed because microthrombi and fibrin deposition are found in IPF lung tissue — but randomized data definitively refuted the hypothesis.

The PANTHER trial similarly showed that the combination of prednisone, azathioprine, and N-acetylcysteine increased hospitalizations and deaths compared to placebo. These findings reinforced that IPF is driven by fibroblast biology, not coagulation or inflammation, and that treatments based on those pathways are not only ineffective but potentially harmful.

What Antifibrotics Actually Do

Pirfenidone (brand name Esbriet) and nintedanib (brand name Ofev) work by different mechanisms but both slow the fibrotic process rather than reversing existing scar tissue. Pirfenidone inhibits TGF-beta-induced collagen synthesis and fibroblast proliferation. Nintedanib blocks multiple receptor tyrosine kinases, including those activated by PDGF, VEGF, and FGF — growth factors that drive fibroblast activation and vascular remodeling.

In the pivotal Phase 3 trials (ASCEND for pirfenidone; INPULSIS for nintedanib), both drugs reduced annual FVC decline by approximately 50% compared to placebo. Neither trial showed a statistically significant improvement in mortality, but patients on active treatment had fewer acute exacerbations and better preserved quality of life over 52 weeks. Both drugs are now recommended as first-line treatment for all patients with IPF, regardless of disease severity.

Pulmonary Hypertension as a Complication

Dr. Erzurum's work on the pathobiology of pulmonary hypertension (cited 568 times) is directly relevant to IPF patients. Up to 40% of patients with IPF develop secondary pulmonary arterial hypertension as the disease progresses — driven by hypoxemia, vascular remodeling, and the mechanical disruption of the pulmonary microvasculature by scar tissue. Her hyperproliferative endothelial cell studies help explain why these vessels behave abnormally under fibrotic conditions.

Secondary pulmonary hypertension in IPF markedly worsens prognosis and is a major driver of functional limitation. Patients with IPF who develop progressive dyspnea disproportionate to their spirometric decline should be evaluated with echocardiography and right heart catheterization.

Lung Transplant: The Only Curative Option

For carefully selected patients with progressive IPF who are otherwise healthy enough for major surgery, bilateral lung transplantation can restore near-normal lung function. Median survival after transplant for IPF is approximately 5 years, substantially longer than without transplant for patients with advanced disease. Referral to a transplant center is recommended for patients under 65 with progressive disease on antifibrotic therapy, before they deteriorate to a point that disqualifies them from surgery.

Questions to ask your doctor

• Should I start antifibrotic therapy now, or is watchful waiting reasonable given my current FVC?
• How often should I have spirometry to track progression, and what decline threshold would change my management?
• Has my echocardiogram been checked for signs of pulmonary hypertension?
• Should I be evaluated at a transplant center, even if I do not need a transplant yet?
• Are there clinical trials I might be eligible for?
• Is oxygen supplementation appropriate for my current saturation levels?

The bottom line

IPF is driven by fibroblast biology, not inflammation — which is why anti-inflammatory drugs not only fail but can cause harm. Pirfenidone and nintedanib reduce the rate of lung function decline by roughly half and should be started early. Because fibrosis creates a self-amplifying mechanical feedback loop, the sooner treatment begins, the more lung function can be preserved. Regular spirometric monitoring, screening for pulmonary hypertension, and early transplant referral for progressive cases are the pillars of modern IPF management.